Johnson & Johnson announced that TREMFYA (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in… read more.
11th October 2026 – AbbVie announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026… read more.
Eli Lilly and Company announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and… read more.
Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is… read more.
Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple… read more.
Tiziana Life Sciences, Ltd. announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy… read more.
Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver… read more.
Telix Pharmaceuticals Limited announces that the first patients in the United States (U.S.) have been dosed with Pixclara (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron… read more.
Novo Nordisk announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglutide… read more.
Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with Mob-015 was achieved across the… read more.
Novartis announced that the FDA approved Rhapsido (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled… read more.
Alterity Therapeutics has presented additional analyses from its randomised, double-blind, placebo-controlled ATH434-201 Phase 2 trial in multiple system atrophy (MSA) at the 2026 International Congress of Parkinson’s Disease… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
